

Bio Convergence - From theory to the clinic Bio Convergence is a combination of biology, engineering and many additional disciplines. Tissue engineering is a field in Bio-convergence that stretches the multi-disciplinary capabilities and requirements to an extreme. Advancements from science to technology over the last 20 years, have not materialized to clinical worthy tissues and products. This is where 3D bio printing steps in and enables sustainable, manufacturable and quality controlled 4D biofabrication that can bring these technologies through regulation to the clinic and to the benefit of patients. Precise bio has developed a unique 3D printing technology with single cell resolution and high viability that can fabricate tissues from human cells mimicking the natural anatomical structure. This session shall present the technologies developed at Precise bio and present examples of 4D bio fabricated tissues that show functionality in preclinical studies and are now being transferred to GMP manufacturing for the clinical studies. Company name: Precise Bio www.precise-bio.com CEO name: Aryeh Batt* number: 0547345607 * CATEGORY: Biotech/Pharma * Select up to two SESSIONS * 1, 12

1. Longevity - How to Complete the Centenarian Decathlon? 12. Bio Convergence - Everything That Rises Must Converge.

- o Core Technology Precise 4D bio fabrication technology is comprised from the unique patented 3D printing technology enabling engineering of vital and functional tissue, together with cell biology, bio materials, engineering process and a multi-disciplinary combination of the technology components
- o Product Profile/Pipeline The company has 3 products in preclinical stage. Corneal graft for EK, lenticules for Keratoconus and vision correction and Retina tissue addressing AMD. The current focus is in the ophthalmology field and precise is building a pipeline of products addressing multibillion unmet therapeutic need in this field. In the future precise will be addressing additional fields as cardiology, orthopedics and other, utilizing Precise's platform technologies and translating them to clinical worthy tissues and organs.
- o Business Strategy Precise is currently focused in the ophthalmology field and is collaborating with multinational corporates in the field both in R&D and commercializing efforts. Precise has signed a strategic agreement with Carl Zeiss Meditech
- o What's Next? Precise is starting GMP manufacturing in May 2023 and targeting clinical studies in 2024. Precise has raised over \$31M in several rounds and is currently raising it's B-Round of 25M.